Comparison of effects of calcitriol and calcium carbonate on secretion of interleukin-1β and tumour necrosis factor-α by uraemic peripheral blood mononuclear cells

Nephrology Dialysis Transplantation

Volumn 11, Issue SUPPL. 3, 1996, Pages 15-21

  Tsukamoto, Y ^a   Nagaba, Y ^a   Izumida, I ^a   Morishita, T ^a   Saitoh, M ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcitriol; Calcium carbonate; IL 1 ; Non dialysed uraemics; Peripheral blood mononuclear cell; TNF

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM CARBONATE; CREATININE; INTERLEUKIN 1BETA; OSTEOCALCIN; PARATHYROID HORMONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; UREMIA;

EID: 0029759095     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.supp3.15     Document Type: Conference Paper

References (39)

1. Smith AJ, Faugere MC, Abreo K, Fanti P, Julian B, Malluche HH. Aluminium-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 1986; 6: 275-283
2. Malluche HH, Ritz E, Lange HP et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976; 9: 355-362
3. Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 1978: 700-703
4. Tougaard L, Sorensen E, Brochner MJ, Christensen MS, Rodbro P, Sorensen AW. Controlled trial of lalphahydroxycholecalciferol in chronic renal failure. Lancet 1976; 1: 1044-1047
5. Coen G, Mazzaferro S, Bonucci E et al. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results. Miner Electrolyte Metab 1986; 12: 375-382
6. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 1988; 67: 929-936
7. Baker LRI, Louise Abrams SM, Roe CJ et al. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35: 661-669
8. Tsukamoto Y, Nomura M, Takahashi Y et al. The 'oral 1,25-Dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991; 57: 23-28
9. Tsukamoto Y, Moriya R, Nagaba Y, Morishita T, Izumida I, Okubo M. Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. Am J Kidney Dis 1995; 25: 879-886
10. Massry SG, Stein R, Garty J et al. Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25(OH)2D3. Kidney Int 1976; 9: 467-474
11. Ritz E, Malluche HH, Krempien B, Tschope W, Massry SG. Pathogenesis of renal osteodystrophy: roles of phosphate and skeletal resistance to PTH. Adv Exp Med Biol 1978; 103: 423-436
12. Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38: 193-211
13. Nussbaum SR, Zahradnik RJ, Lavigne JR et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364-1367
14. Hosoda K, Eguchi H, Nakamoto T et al. A sandwich immunoassay for intact human osteocalcin. Clin Chem 1992; 38: 2233-2238
15. Hosoda K, Kanzaki S, Eguchi H et al. Secretion of osteocalcin and its propeptide from human osteoblastic cells: dissociation of the secretory patterns of osteocalcin and its propeptide. J Bone Miner Res 1993; 8: 553-565
16. Stepan JJ, Silinkova ME, Havranek T et al. Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 1983; 133: 189-200
17. Bertoli M, Luisetto G, Ruffatti A, Urso M, Romagnoli G. Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 1990; 33: 98-102
18. Cochran M, Wilkinson R. Effect of correction of metabolic acidosis on bone mineralisation rates in patients with renal osteomalacia. Nephron 1975; 15: 98-110
19. Kraut JA, Gordon EM, Ransom JC, Coburn JW, Kurokawa K. The effect of chronic metabolic acidosis on the end organ responsiveness to parathyroid hormone in man. J Clin Endocrinol Metab 1983; 56: 619-622
20. Lefebvre A, de VM, Gueris J, Goldfarb B, Graulet AM, Morieux C. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989; 36: 1112-1118
21. Naik RB, Gosling P, Price CP. Comparative study of alkaline phosphatase isoenzymes, bone histology, and skeletal radiography in dialysis bone disease. Br Med J 1977; 1: 1307-1310
22. Nishimoto SK, Price PA. Secretion of the vitamin K-dependent protein of bone by rat osteosarcoma cells. J Biol Chem 1980; 255: 6579-6583
23. Lian JB, Friedman PA. The vitamin K-dependent synthesis of carboxyglutamate, in mineralyzed tissue. J Biol Chem 1978; 253: 6623-6626
24. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla protein, a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984; 19: 1091-1093
25. Charhon SA, Delmas PD, Malaval L et al. Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Melab 1986; 63: 892-897
26. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps LB. Influence of first and long-term dialysis on uraemia-associated increased basal production of interleukin-1 and tumour necrosis factor alpha by circulating monocytes. Nephrol Dial Transplant 1991; 6: 349-357
27. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps LB. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990; 37: 116-125
28. Powell AC, Bland LE, Oettinger CW et al. Lack of plasma interleukin-1 beta or tumor necrosis factor-alpha elevation during unfavorable hemodialysis conditions. J Am Soc Nephrol 1991; 2: 1007-1013
29. Haran N, Gurwicz S, Gallati H, Shalita B, Bar-Khayim Y. Effect of 1α-hydroxyvitamin D3 treatment on production of tumor necrosis factor-α by peripheral blood mononuclear cells and on serum concentrations of soluble tumor necrosis factor receptors in hemodialysis patients. Nephron 1994; 66: 262-266
30. Riancho JA, Zarrabeitia MT, de Francisco AL et al. Vitamin D therapy modulates cytokine secretion in patients with renal failure. Nephron 1993; 65: 364-368
31. Garrett IR, Guise TA, Bonewald LF, Chizzonite R, Mundy GR. Evidence that interleukin-1 mediates its effects on bone resorption via the 80 kilodalton interleukin-1 receptor. Calcif Tissue Int 1993; 52: 438-441
32. Guise TA, Garrett IR, Bonewald LF, Mundy GR. Interleukin-1 receptor antagonist inhibits the hypercalcemia mediated by interleukin-1. J Bone Miner Res 1993; 8: 583-587
33. Schneider HG, Allan EH, Moseley JM, Martin TJ, Findlay DM. Specific down-regulation of parathyroid hormone (PTH) receptors and responses to PTH by tumour necrosis factor alpha and retinoic acid in UMR 106-06 osteoblast-like osteosarcoma cells. Biochem J 1991; 280: 451-457
34. Hanevold CD, Yamaguchi DT, Jordan SC. Tumor necrosis factor alpha modulates parathyroid hormone action in UMR-106-01 osteoblastic cells. J Bone Miner Res 1993; 8: 1191-1200
35. Taichman RS, Hauschka PV. Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro. Inflammation 1992; 16: 587-601
36. Kuno H, Kurian SM, Hendy GN et al. Inhibition of 1,25-dihydroxy vitamin D3 stimulated osteocalcin gene transcription by tumor necrosis factor-alpha: structural determinants within the vitamin D response element. Endocrinology 1994; 134: 2524-2531
37. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993; 43: 436-442
38. Hernandez D, Conception MT, Lorenzo V et al. Adynamic bone disease with negative aluminum staining in predialysís patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994; 9: 517-523
39. Bianchi ML, Colantonio G, Campanini F et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 1994; 9: 1595-1599